Literature DB >> 25359580

Antimicrobial susceptibility profiles, serotype distribution and virulence determinants among invasive, non-invasive and colonizing Streptococcus agalactiae (group B streptococcus) from Malaysian patients.

N Eskandarian1, Z Ismail, V Neela, A van Belkum, M N M Desa, S Amin Nordin.   

Abstract

A total of 103 group B streptococci (GBS) including 22 invasive, 21 non-invasive, and 60 colonizing isolates were collected in a Malaysian hospital (June 2010-October 2011). Isolates were characterized by conventional and molecular serotyping and analyzed for scpB, lmb, hylB, cylE, bac, bca and rib gene content. Antimicrobial susceptibility to penicillins, macrolides, lincosamides, quinolones and tetracyclines was determined using disk diffusion and the MICs for penicillin were determined by E-test. Molecular serotyping for all eight serotypes (Ia, Ib, II-VII) was in full accordance with conventional serotyping. Overall, taking CS and MS together, serotype VI was the most common capsular type (22.3 %) followed by VII (21.4 %), III (20.4 %), Ia (17.5 %), V (9.7 %), II (7.7 %) and IV (1 %). Susceptibility to beta-lactam antimicrobials was prevalent (100 %). Resistance rates for erythromycin, clindamycin and tetracycline were 23.3 %, 17.5 % and 71.8 %, respectively. PCR-virulence gene screening showed the presence of cylE, lmb, scpB and hylB in almost all the isolates while rib, bca, and bac genes were found in 29.1 %, 14.6 % and 9.7 % of the isolates. Certain genes were significantly associated with specific serotypes, namely, rib with serotypes Ia, II, III and VI; bca and bac with serotypes II and III. Furthermore, serotype Ia was significantly more common among patients with invasive infections (p < 0.01) and serotype VI isolates were significantly more common among carriers (p < 0.05). In summary, serotype distribution correlates with virulence gene content will be useful in epidemiological studies and design of vaccines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359580      PMCID: PMC4356882          DOI: 10.1007/s10096-014-2265-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


Introduction

Streptococcus agalactiae, the group B streptococcus (GBS), is a gram-positive and encapsulated bacterium, which displays beta-hemolytic activity on blood agar. It is part of the commensal flora in the genital and lower gastrointestinal tracts in 10–40 % of healthy adults [1]. However, vaginal colonization by GBS during pregnancy may be clinically significant because it is associated with neonatal meningitis and septicemia [2]. During recent decades, GBS infection has increasingly emerged in adults, particularly those with underlying illness such as diabetes [3]. Penicillin is the first-line agent for prevention and treatment of GBS infections [1, 4]; however, since 1994, GBS isolates with reduced susceptibility to penicillin have been reported periodically [5]. In case of penicillin allergy, clindamycin and erythromycin are the most recommended alternatives. Consequently, the increasing use of these drugs, consumed by around 20 % of all GBS carriers, resulted in elevated rates of clindamycin and erythromycin resistance worldwide [6, 7]. Capsular serotype contributes to disease severity and defines vaccine development [8]. Ten GBS capsular types have been identified (Ia, Ib and II-IX) and vaccination against five serotypes (Ia, Ib, II, III and V) is in development [7, 9]. Several investigations revealed that strains harboring the CPS types Ia, II, III, and V are the most significant causes of GBS invasive disease in neonates and other patients [10, 11]. PCR can identify serologically non-typable strains since these generally still carry the required genes [12]. Therefore, molecular serotyping techniques have an elevated discriminatory power for epidemiological studies [13]. GBS has many virulence factors including surface proteins, toxins and hydrolytic enzymes [14]. Surface proteins mostly function as adhesins, which may also contribute to immune evasion. These include C5a peptidase (ScpB), laminin-binding protein (Lmb), the α and β-subunits of C protein (Bca and Bac) and Rib protein. GBS secrete a variety of toxins such as β-hemolysin/cytolysin (cylE), hyaluronidase (hylE) and the CAMP factor (cfb) which facilitate entry of GBS into host cells and promote its intra-cellular survival [15]. Epidemiological studies on GBS, assessment of their antibiotic susceptibility and conventional serotyping are sparse in Malaysia. Molecular serotyping and virulence determinants of Malaysian GBS are published for the first time in this study.

Materials and methods

Bacterial isolates

A total of 103 pure cultures of GBS were obtained from outpatients and inpatients at the Universiti Kebangsaan Malaysia Medical Centre (UKMMC), a 900-bed teaching and referral hospital in Malaysia (June 2010–October 2011). Isolates were grouped into three different types based on the clinical outcome and site of isolation: invasive (n =22) for isolates derived from normally sterile body site such as blood; non-invasive isolates (n =21) for isolates derived from wound and skin ulcers, tracheal and gastric aspirates; colonizing isolates (n =60) derived from vaginal swabs and urine samples from asymptomatic patients. Basically, pure GBS cultures were obtained except for 10 (9.7 %) cases in which GBS coexisted with other organisms (e.g. Staphylococcus aureus, coagulase-negative staphylococci, Escherichia coli, Pseudomonas aeruginosa, Klebsiella species or unspecified gram positive and negative cocci). Identification was carried out based on culture characteristics, Gram staining, catalase testing and CAMP testing. The species nature of the isolates was confirmed by slide agglutination using Streptex (Murex Diagnostics, UK) and by conventional PCR assays targeting the cfb gene (encoding the CAMP factor). All strains were preserved in sterile nutrient broth with 15 % glycerol and on beads in cryo-vials (Pro-Lab, UK) at −70 °C for long-term storage and on 5 % sheep blood agar plates at 4 °C for short-term maintenance.

Serotyping

Capsular serotyping was performed by the latex agglutination method using antisera specific for each capsular type (Ia, Ib, II-VII) using Strep-B-Latex kits (Statens Serum Institute, SSI, Sweden). Isolates that did not react with any of the antisera were classified as serologically non-typeable (NT). Further confirmation of capsular types was performed for all strains using PCR. The conventional PCR assay as developed for seven GBS capsular types (Ia-VII) and targeting the cps gene cluster was used according to Borchardt et al. [16]. DNA was extracted using GeneAll Exgene Mini genomic extraction kits (GeneAll, South Korea) following the manufacturer’s instructions. The GBS reference strains A909 (type Ia), H36B (type Ib), 18RS21 (type II), M78 (type III), CNCTC 1/82 (type IV), BAA-611 (type V), NT6 (type VI), 7271 SSI (type VII) were kindly provided by Universiti Kebangsaan Malaysia Medical Centre.

Antimicrobial susceptibility testing

Antibiotic susceptibility testing (AST) was performed by the disc diffusion (Kirby-Bauer) method according to the guidelines described by CLSI in 2012 [17]. The panel of antibiotics included penicillins (penicillin G and ampicillin), cephalosporins (cefuroxime and ceftriaxone), a quinolone (levofloxacin), a glycopeptide (vancomycin), a macrolide (erythromycin), a lincosamide (clindamycin), a phenicole (chloramphenicol) and tetracycline. The MIC for penicillin was determined using the Etest® strip (bioMérieux, Marcy l’Etoile, France). Each batch of tests was run concurrently with Streptococcus pneumoniae ATCC 49619 as quality control. The diameters of the inhibition zones and MICs were interpreted based on CLSI interpretation guidelines (2012) [17]. Erythromycin resistant, clindamycin sensitive strains were further tested by the double-disc diffusion method (D-zone test) with erythromycin and clindamycin disks 12 mm apart. Strains with D-shaped clindamycin zones (inducible clindamycin resistance) were considered as “clindamycin resistant”.

Determination of virulence genes

All GBS isolates were screened for the presence of seven virulence genes, namely, scpB, lmb, hylB, cylE, bac, bca and rib encoding C5a peptidase, laminin binding protein, hyaluronate lyase, β-hemolysin/cytolysin, β-C protein, α-C protein and Rib protein by using PCR. The oligonucleotide primers and PCR cycling conditions were as reported by others [18-21]. The GBS reference strains, ATCC 13813 (cfb), ATCC BAA-611 (rib), NCTC 11078 (bca, and bac), ATCC 12403 (cylE), ATCC 12386 (lmb and scpB) and Streptococcus agalactiae, strain 4755 (hylB), were included as positive controls.

Statistical analysis

The SPSS statistical analysis package (version 21.0 for Windows) was used to analyze the significance of the results. Chi-square tests of independence were performed to assess possible associations between the variables. The significance level was set at p <0.05. If the chi-square test of independence was statistically significant, then post-hoc comparison tests were conducted to determine the variable that produced the statistically most significant difference. The obtained standard residual (std.res) from post-hoc analysis was considered significant when std.res >1.96, >2.58 and >3.33 were at 0.05, 0.01 and 0.001 level of significance.

Results

Clinical data of all patients are summarized in Table 1. Among the 103 GBS isolates, 11 (10.7 %) were from neonates, all of whom presented with early-onset disease (<7 days old) and more than half of the neonates (64 %) were known to have GBS bacteremia. Ninety-two isolates (89.3 %) were recovered from adults (age range 20–87). In non-pregnant adults (n =43), GBS isolates were often isolated from blood (37.3 %), vagina (35 %), wound and abscess specimens (26 %). Urine sample yielded only one isolate (1.7 %). Among pregnant women, most of the GBS isolates were recovered from vaginal specimens (90 %). Blood, urine and placenta swabs yielded a few additional isolates (10 %).
Table 1

Distribution of 103 GBS isolates among patient groups

Patient groupNo. (%) of patientsInvasive populationNon-invasive populationColonizing populationTotal
Neonate11 (10.7)74011
Pregnant adults49 (47.6)034649
Non-pregnant adults43 (41.7)15141443
Total103 (100)222160103
Distribution of 103 GBS isolates among patient groups

Comparison of conventional serotyping (CS) with molecular serotyping (MS)

CS was able to identify the capsular serotypes of 80.6 % (83/103) of the GBS isolates studied and 20 (19.4 %) isolates remained non-typable. All GBS isolates were also tested by MS in order to confirm the accuracy of CS. MS was in accordance with CS for the CS-typeable isolates. MS was able to detect capsular serotype genes in all 20 (19.4 %) serologically non-typable isolates. Six isolates showed serotype III while the remaining 14 isolates were of serotype VII. Overall, taking CS and MS together, serotype VI was the most common capsular type (n =23, 22.3 %) followed by VII (n =22, 21.4 %), III (n =21, 20.4 %), Ia (n =18, 17.5 %), V (n =10, 9.7 %), II (n =8, 7.7 %) and IV (n =1, 1 %). No serotype Ib isolates were found in the present study.

Antimicrobial susceptibility profiles

All GBS strains were susceptible to penicillin G, ampicilin, cefuroxime, ceftriaxone, levofloxacin, vancomycin and chloramphenicol. A hundred percent susceptibility to penicillin was also confirmed by E-test where the MIC ranged from 0.023 to 0.064 μg/ml. The AST results showed that the majority of isolates (n =74, 71.8 %) were resistant to tetracycline. Twenty-four isolates (23.3 %) were resistant to erythromycin and 18 (17.5 %) to clindamycin. Only one case of the 18 resistant isolates showed inducible clindamycin resistance.

PCR amplification of the virulence genes

All isolates were positive for the cfb gene, which helped to confirm the species identity of GBS. Genes encoding the -hemolysin/cytolysin (H/C), laminin binding protein, C5a peptidase, and hyaluronate lyase (cylE, lmb, scpB and hylB) were present in 97.1 %, 97.1 %, 96.1 % and 94.2 % of isolates, respectively, making them the predominant virulence genes. The rib, bca, and bac genes were found in 29.1 %, 14.6 % and 9.7 % of the isolates, respectively.

Association of genotypic traits with molecular serotyping

The distribution of three genotypic traits (bac, bca, rib) and various serotypes are presented in Table 2. As cylE, lmb, scpB, hylB were detected in almost all GBS isolates (97.1 %, 97.1 %, 96.1 %, 94.2 %, respectively), these were excluded from the analysis. Serotype IV was detected only once and was also excluded. The rib gene is significantly associated with serotype Ia, VI (p < 0.05), II and III (p < 0.01). The bca gene was more common among serotype II (p < 0.001) and III (p < 0.01) strains. A significant association was also found between the bac gene and serotype II (p < 0.001) and III (p < 0.05) (Table 2).
Table 2

Association between capsular serotype and virulence genes in 103 isolates of group B streptococcus

Serotype rib + p-value bca + p-value bac + p-value
Ia1 (5.0 %)< 0.050 (0.0 %)> 0.050 (0.0 %)> 0.05
II7 (87.5 %)< 0.017 (87.5 %)< 0.0015 (62.5 %)< 0.001
III12 (63.2)< 0.018 (42.1 %)< 0.0015 (26.3 %)< 0.01
V3 (37.5 %)> 0.050 (0.0 %)> 0.050 (0.0 %)> 0.05
VI2 (7.7 %)< 0.050 (0.0 %)> 0.050 (0.0 %)> 0.05
VII5 (23.8 %)> 0.050 (0.0 %)> 0.050 (0.0 %)> 0.05
Total30 (29.4)15 (14.7 %)10 (9.8 %)

rib + , bca + and bac+ indicates presence of rib, bca and bac genes

std. res >1.96, p < 0.05

std. res >2.58, p < 0.01

std. res >3.33, p < 0.001

Association between capsular serotype and virulence genes in 103 isolates of group B streptococcus rib + , bca + and bac+ indicates presence of rib, bca and bac genes std. res >1.96, p < 0.05 std. res >2.58, p < 0.01 std. res >3.33, p < 0.001 Although all serotypes were observed among the three populations studied, serotype Ia was significantly more common among patients with invasive infections (p < 0.01) and serotype VI isolates were significantly more common among carriers (p < 0.05) (Table 3).
Table 3

Distribution of the serotypes within the studied GBS populations

SerotypeInvasive populationNon-invasive populationColonizing population
Ia10 (45.5)**6 (28.6)2 (3.4)
II1 (4.5)0 (0.0)7 (11.8)
III2 (9.1)4 (19.0)15 (25.0)
V1 (4.5)2 (9.5)7 (11.8)
VI3 (13.7)3 (14.3)17 (30.0)*
VII5 (22.7)6 (28.6)11 (18.0)

*p < 0.05, **p < 0.01

Distribution of the serotypes within the studied GBS populations *p < 0.05, **p < 0.01 No statistically significant associations were found between the virulence genes and the isolate status or age of patients in the present study (p >0.05).

Discussion

In Malaysia, data on detection of GBS virulence genes and molecular serotyping are non-existent. In the present research, GBS isolates were serotyped by both phenotypic and genotypic approaches and further characterized for their virulence patterns and antibiotic susceptibility profiles. Serotype distribution of GBS isolates has previously been reported to vary geographically [9, 22]. In the present study, MS results showed serotype VI (22.2 %) to be overrepresented in the Malaysian population. In contrast, an older study found lower numbers of serotype VI isolates among adults and neonates [23]. Serotype VII is rarely reported worldwide [7, 24, 25]; however, we found a relatively high number of strains with serotype VII (n =22, 21.3 %) among Malaysians. Only eight GBS isolates from our study were CPS type II while a cross-sectional study in South East Asia reported this type as predominant among pregnant women [22]. Serotype Ia was significantly more common among patients with invasive infections (p < 0.01) and serotype VI isolates were significantly more common among carriers (p < 0.05). All isolates were typable by MS, while a considerable proportion (19.4 %) of isolates could not be typed by CS, as also observed in previous studies [9, 26, 27]. The overall beta-lactam susceptibility of Malaysian GBS was confirmed here [1, 4, 22]. Neither penicillin-resistant nor penicillin intermediate GBS strains were detected. Some investigations have identified GBS isolates with reduced sensitivity [5, 28, 29]. Hence, penicillin could still be used as a first-line drug for intra-partum prophylaxis and treatment of GBS infections in Malaysia. The rates of resistance to erythromycin and clindamycin were lower than those in the studies from Japan, Europe and the United States [30, 31], but can be considered high in comparison to the studies from Asian countries [32, 33]. The resistance documented for erythromycin and clindamycin provides a warning that these drugs need to be prescribed with care since also non-susceptible GBS were observed in the United States and Japan [28, 34]. The frequency of virulence gene rib presence is similar to other studies from Europe, the United States and Lebanon [15, 18, 35] and higher than those reported among pregnant women in Poland and Kuwait [14, 36]. The bca encodes -C surface protein (ACP) was observed in a lower frequency than in previous reports, where its presence varied from 42 to 85 % [15, 36, 37]. Another study has identified the bca gene in 100 % of strains; however, in this case only potentially clonal type Ia strains were tested [38]. The bac gene was found at a lower frequency (9.7 %) as compared to other studies from the United States, Europe and New Zealand [7, 18, 39]. A recent study among pregnant women in Kuwait detected bac in only 3.2 % of isolates [37]. Certain virulence genes were significantly more prevalent in given CPS types. For instance, rib was associated significantly with serotypes Ia, II, III and VI. Previous data from South East Asian countries and Europe confirmed the association between rib gene and serotype Ia, II and III [39-42]. Moreover, our results indicated a significant association between serotypes II and III with bca and bac, while other studies demonstrated association between bca and bac with serotype Ib and II [35, 39, 41]. According to Duarte et al. (2005) around 30–55 % of serotype Ia GBS isolates in humans harbored the bca gene [20]. In another study reported by Dore et al. around 50 % of serotype III isolates harbored the bca or bac or both [42]. This difference may be caused by geographical differences in prevalence or may indicate the appearance of silent bca and bac genes in these serotypes. The present study could not demonstrate any correlation between the virulence genes and clinical status of the patients from whom the isolates were obtained (p >0.05); however, as pointed out by Maning et al. invasive isolates showed a tendency to have rib and bac [18]. No significant associations were found between the occurrence of virulence genes and the age of patients in the present study (p >0.05). However, based on data presented by Ho et al. the majority of bca genes (85.4 %) in GBS isolates were observed in strains from adults, whereas 59.2 % of rib gene was harbored among isolates from neonates [40]. Given the lack of correlation we describe above, our data do not confirm the virulence potential of the genes detected. In conclusion, our GBS collection contained a high number of strains with serotypes VI and VII, in contrast to findings in other countries [7, 24, 43]. Such differences in the relative regional incidence of serotypes could compromise the efficacy of vaccine. Additionally, the present study clearly shows the equivalence of MS and CS and indicates the broader coverage of MS. Data presented here confirms previous findings on the relationship between different virulence genes and serotypes but fails to confirm the virulence contribution of the panel of potential virulence genes we screened for.
  41 in total

1.  Distribution and expression of bca, the gene encoding the c alpha protein, by Streptococcus agalactiae.

Authors:  J A Maeland; O G Brakstad; L Bevanger; S Krokstad
Journal:  J Med Microbiol       Date:  2000-02       Impact factor: 2.472

2.  Simultaneous detection and serotype identification of Streptococcus agalactiae using multiplex PCR and reverse line blot hybridization.

Authors:  Fanrong Kong; Lin Ma; Gwendolyn L Gilbert
Journal:  J Med Microbiol       Date:  2005-12       Impact factor: 2.472

3.  Distribution of antimicrobial resistance and virulence-related genes among Brazilian group B streptococci recovered from bovine and human sources.

Authors:  Rafael S Duarte; Bruna C Bellei; Otávio P Miranda; Maria A V P Brito; Lúcia M Teixeira
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiae.

Authors:  Monica Imperi; Marco Pataracchia; Giovanna Alfarone; Lucilla Baldassarri; Graziella Orefici; Roberta Creti
Journal:  J Microbiol Methods       Date:  2009-12-01       Impact factor: 2.363

5.  Reverse line blot assay for direct identification of seven Streptococcus agalactiae major surface protein antigen genes.

Authors:  Zuotao Zhao; Fanrong Kong; Gwendolyn L Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Serotypes and antibiotic resistance in Group B streptococcus isolated from patients at the Maternity Hospital, Kuwait.

Authors:  Samar S Boswihi; Edet E Udo; Noura Al-Sweih
Journal:  J Med Microbiol       Date:  2011-09-08       Impact factor: 2.472

7.  Group B streptococcal bacteremia in a major teaching hospital in Malaysia: a case series of eighteen patients.

Authors:  N Eskandarian; V Neela; Z Ismail; S M Puzi; R A Hamat; M N M Desa; S A Nordin
Journal:  Int J Infect Dis       Date:  2013-02-28       Impact factor: 3.623

8.  Comparison of DNA dot blot hybridization and lancefield capillary precipitin methods for group B streptococcal capsular typing.

Authors:  Stephanie M Borchardt; Betsy Foxman; Donald O Chaffin; Craig E Rubens; Patricia A Tallman; Shannon D Manning; Carol J Baker; Carl F Marrs
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

9.  Group B streptococcal carriage, serotype distribution and antibiotic susceptibilities in pregnant women at the time of delivery in a refugee population on the Thai-Myanmar border.

Authors:  Claudia Turner; Paul Turner; Linda Po; Naw Maner; Aruni De Zoysa; Baharak Afshar; Androulla Efstratiou; Paul T Heath; François Nosten
Journal:  BMC Infect Dis       Date:  2012-02-08       Impact factor: 3.090

10.  Detection of Group B Streptococcus in Brazilian pregnant women and antimicrobial susceptibility patterns.

Authors:  Didier Silveira Castellano-Filho; Vânia Lúcia da Silva; Thiago César Nascimento; Marcel de Toledo Vieira; Cláudio Galuppo Diniz
Journal:  Braz J Microbiol       Date:  2010-12-01       Impact factor: 2.476

View more
  12 in total

Review 1.  Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Clin Microbiol Rev       Date:  2018-08-15       Impact factor: 26.132

2.  Molecular epidemiology and distribution of serotypes, genotypes, and antibiotic resistance genes of Streptococcus agalactiae clinical isolates from Guelma, Algeria and Marseille, France.

Authors:  A Bergal; L Loucif; D E Benouareth; A A Bentorki; C Abat; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-28       Impact factor: 3.267

3.  Natural Mutations in Streptococcus agalactiae Resulting in Abrogation of β Antigen Production.

Authors:  Anastasia Vasilyeva; Ilda Santos Sanches; Carlos Florindo; Alexander Dmitriev
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

4.  Genomic characterisation of perinatal Western Australian Streptococcus agalactiae isolates.

Authors:  Lucy L Furfaro; Barbara J Chang; Charlene M Kahler; Matthew S Payne
Journal:  PLoS One       Date:  2019-10-02       Impact factor: 3.240

5.  Clinical and Microbiological Characteristics of Group B Streptococcus from Pregnant Women and Diseased Infants in Intrapartum Antibiotic Prophylaxis Era in Taiwan.

Authors:  Chien-Chung Lee; Jen-Fu Hsu; Rajendra Prasad Janapatla; Chyi-Liang Chen; Ying-Li Zhou; Reyin Lien; Cheng-Hsun Chiu
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

6.  Determinants of Group B streptococcal virulence potential amongst vaginal clinical isolates from pregnant women.

Authors:  Lindsey R Burcham; Brady L Spencer; Lauryn R Keeler; Donna L Runft; Kathryn A Patras; Melody N Neely; Kelly S Doran
Journal:  PLoS One       Date:  2019-12-18       Impact factor: 3.240

7.  Analysis of virulence factors and antibiotic resistance genes in group B streptococcus from clinical samples.

Authors:  Raymond Mudzana; Rooyen T Mavenyengwa; Muchaneta Gudza-Mugabe
Journal:  BMC Infect Dis       Date:  2021-01-28       Impact factor: 3.090

8.  Virulence factors and antibiotic resistance properties of Streptococcus species isolated from hospital cockroaches.

Authors:  Mohammad Chehelgerdi; Reza Ranjbar
Journal:  3 Biotech       Date:  2021-06-10       Impact factor: 2.893

9.  Genetic Diversity and Antimicrobial Drug Resistance of Serotype VI Group B Streptococcus, Canada.

Authors:  Alefiya Neemuchwala; Sarah Teatero; Lindsay Liang; Irene Martin; Walter Demzcuk; Allison McGeer; Nahuel Fittipaldi
Journal:  Emerg Infect Dis       Date:  2018-10       Impact factor: 6.883

10.  Group B Streptococcus colonization rate and serotype distribution among pregnant women and their newborns at Adama Hospital Medical College, Ethiopia.

Authors:  Musa Mohammed Ali; Daniel Asrat; Demissie Assegu Fenta; Tolossa Eticha Chaka; Yimtubezinash Woldeamanuel
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.